Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.
- Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies.
- Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital.
- The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover.
Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change that, with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis and the acute cognitive and physiological effects of alcohol intoxication.
Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS around the work; about one million of those living in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of males. The prevalence of the disease is also increasing.
The disease attacks the myelin sheath, the protective coating surrounding nerve fibers in the brain and spinal cord. When myelin is damaged, communication between the brain and body breaks down. The result can be numbness, vision problems, mobility impairment, cognitive difficulties and, over time, serious and lasting disability.
Available treatments can slow the progression of the disease and can even reduce relapses, but no existing options have been shown to reliably halt or reverse the underlying nerve damage. Companies are working to change that: The global MS therapeutics market was valued at approximately $27.4 billion in 2024 and is projected to reach $38.6 billion by 2030, a reflection of how large and persistent the unmet clinical need remains.
Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Rather than modulating the immune system, Lucid-MS targets protein arginine deiminase 2 (“PAD2”), an enzyme directly involved in myelin degradation. The goal is to protect and potentially restore the myelin sheath itself, addressing the underlying cause of disability rather than managing symptoms.
In preclinical animal models, Lucid-MS accelerated functional recovery, preserved myelin and reduced damage in MS mouse models. Phase 1 clinical trials in healthy human volunteers confirmed a favorable safety profile, with the drug well tolerated and no significant safety concerns reported. In March 2026, the company submitted an Investigational New Drug application to the U.S. FDA for a phase 2 trial.
In April 2026, the company announced that it had formally submitted an Investigational New Drug application to the U.S. FDA for a phase 2 clinical trial of Lucid-MS in people with multiple sclerosis.
Supporting the phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital. The study uses a novel PET imaging tracer, [¹⁸F]3F4AP], developed by researchers at MGH and Harvard Medical School. The tracer is designed to directly visualize demyelinated neurons with intact axons, offering a more precise way to measure myelin damage and repair than any currently available technique. Enrollment in the pilot study recently reached its halfway point, with early imaging data showing a robust signal in acute MS lesions.
Alcohol’s impact on the brain is Quantum BioPharma’s second area of focus. Alcohol is one of the most widely consumed and heavily studied psychoactive substances on the planet, responsible for an estimated 2.6 million deaths annually. Alcohol use impairs cognition, slows reaction times, disrupts physiological function and contributes to an enormous global burden of harm. The science has long held that once alcohol enters the bloodstream, only time can metabolize it, approximately one standard drink per hour. Quantum BioPharma challenged that assumption.
The science has long held that once alcohol enters the bloodstream, only time can metabolize it, approximately one standard drink per hour, as the liver processes alcohol at a largely fixed rate. Quantum BioPharma challenged that assumption.
The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. In a double-blind, randomized, placebo-controlled clinical trial, unbuzzd reduced blood alcohol concentration more than 40% faster than placebo within the first 30 minutes after consumption. Participants also reported statistically significant improvements in alertness, reduced headache severity and fewer symptoms of impairment. No adverse side effects were reported.
Those results were published in the “World Journal of Pharmaceutical and Medical Research” earlier this year. The publication marked a meaningful scientific validation for a product, available online, that now sits at the intersection of consumer wellness and clinical evidence.
Together, Lucid-MS and unbuzzd reflect a company committed to applying rigorous science where existing solutions have fallen short. Quantum BioPharma is advancing both assets with clinical data, peer-reviewed evidence and regulatory engagement, bringing genuine scientific innovation to two areas where patients have long needed better answers.
For more information, visit www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.
- Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies.
- Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital.
- The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover.
Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change that, with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis and the acute cognitive and physiological effects of alcohol intoxication.
Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS around the work; about one million of those living in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of males. The prevalence of the disease is also increasing.
The disease attacks the myelin sheath, the protective coating surrounding nerve fibers in the brain and spinal cord. When myelin is damaged, communication between the brain and body breaks down. The result can be numbness, vision problems, mobility impairment, cognitive difficulties and, over time, serious and lasting disability.
Available treatments can slow the progression of the disease and can even reduce relapses, but no existing options have been shown to reliably halt or reverse the underlying nerve damage. Companies are working to change that: The global MS therapeutics market was valued at approximately $27.4 billion in 2024 and is projected to reach $38.6 billion by 2030, a reflection of how large and persistent the unmet clinical need remains.
Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Rather than modulating the immune system, Lucid-MS targets protein arginine deiminase 2 (“PAD2”), an enzyme directly involved in myelin degradation. The goal is to protect and potentially restore the myelin sheath itself, addressing the underlying cause of disability rather than managing symptoms.
In preclinical animal models, Lucid-MS accelerated functional recovery, preserved myelin and reduced damage in MS mouse models. Phase 1 clinical trials in healthy human volunteers confirmed a favorable safety profile, with the drug well tolerated and no significant safety concerns reported. In March 2026, the company submitted an Investigational New Drug application to the U.S. FDA for a phase 2 trial.
In April 2026, the company announced that it had formally submitted an Investigational New Drug application to the U.S. FDA for a phase 2 clinical trial of Lucid-MS in people with multiple sclerosis.
Supporting the phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital. The study uses a novel PET imaging tracer, [¹⁸F]3F4AP], developed by researchers at MGH and Harvard Medical School. The tracer is designed to directly visualize demyelinated neurons with intact axons, offering a more precise way to measure myelin damage and repair than any currently available technique. Enrollment in the pilot study recently reached its halfway point, with early imaging data showing a robust signal in acute MS lesions.
Alcohol’s impact on the brain is Quantum BioPharma’s second area of focus. Alcohol is one of the most widely consumed and heavily studied psychoactive substances on the planet, responsible for an estimated 2.6 million deaths annually. Alcohol use impairs cognition, slows reaction times, disrupts physiological function and contributes to an enormous global burden of harm. The science has long held that once alcohol enters the bloodstream, only time can metabolize it, approximately one standard drink per hour. Quantum BioPharma challenged that assumption.
The science has long held that once alcohol enters the bloodstream, only time can metabolize it, approximately one standard drink per hour, as the liver processes alcohol at a largely fixed rate. Quantum BioPharma challenged that assumption.
The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. In a double-blind, randomized, placebo-controlled clinical trial, unbuzzd reduced blood alcohol concentration more than 40% faster than placebo within the first 30 minutes after consumption. Participants also reported statistically significant improvements in alertness, reduced headache severity and fewer symptoms of impairment. No adverse side effects were reported.
Those results were published in the “World Journal of Pharmaceutical and Medical Research” earlier this year. The publication marked a meaningful scientific validation for a product, available online, that now sits at the intersection of consumer wellness and clinical evidence.
Together, Lucid-MS and unbuzzd reflect a company committed to applying rigorous science where existing solutions have fallen short. Quantum BioPharma is advancing both assets with clinical data, peer-reviewed evidence and regulatory engagement, bringing genuine scientific innovation to two areas where patients have long needed better answers.
For more information, visit www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
